Soft Push Tabs for Catheter Adapter

The European Patent Office published patent application EP4233968A2 for Becton, Dickinson and Company's catheter adapter with soft push tabs. The patent application names five inventors including Michael Garrison and Bart Peterson, covering catheter technology in IPC classifications A61M 25/00, A61M 25/06, and A61M 25/02. The application designates all EU member states plus other EPC contracting states.

Pharmaceutical Composition for Prevention or Treatment of Post-Surgical Pain

EPO published patent application EP4084818A2 by Peptinov covering a pharmaceutical composition for preventing or treating post-surgical pain. The composition is classified under IPC codes A61K 38/17, A61K 38/20, and A61P 29/00, with inventors including Azoulai, Cassard, Salles, and Zagury. Designated states cover 31 European countries including major markets.

Pilocarpine Micro-Dose Composition for Treating Presbyopia

The European Patent Office published patent application EP3934643A1 filed by Hyperion DeFi, Inc., covering a pilocarpine micro-dose composition delivered as a stream of droplets for treating presbyopia. The application names inventors Ianchulev and Clauson. The patent is classified under A61K (medicinal preparations), A61P 27/02 (ophthalmologicals), and B05B (atomizing devices).

Treatment of Cancer with LGR5/EGFR Antibody and Topoisomerase I Inhibitor

The European Patent Office published patent application EP4017879A2 by Merus B.V. for a cancer treatment combining an antibody targeting LGR5 and EGFR with a topoisomerase I inhibitor. The invention covers therapeutic compositions and methods for treating cancer, with designated states including major European markets (DE, FR, GB, NL, IT, ES, etc.).

CD3 Binding Molecules Patent for Anticancer Antibodies

The European Patent Office published patent application EP3947456A1 for Merus B.V., covering CD3 binding molecules and anticancer antibodies. The patent was published on March 25, 2026, with inventor Pieter Fokko van Loo. The application covers therapeutic uses related to A61P 35/00 (antineoplastic agents).

Iadademstat Combinations Cancer Therapy Patent

The European Patent Office published patent EP3946295A1 for Oryzon Genomics, S.A., covering combinations of iadademstat (an LSD1 inhibitor) with other therapeutic agents for cancer treatment. The patent application was filed by inventor Filippo Ciceri with designated states across 35 European countries. This patent grant provides intellectual property protection for the pharmaceutical company's cancer therapy combinations.

Gamma-hydroxybutyrate compositions having improved fed-state pharmacokinetics

The European Patent Office published patent application EP3930702A1 by Flamel Ireland Limited for gamma-hydroxybutyrate compositions with improved pharmacokinetic properties in the fed state. The patent covers therapeutic formulations and is classified under A61P 43/00 (therapeutic activity). This routine patent publication provides intellectual property protection for the disclosed pharmaceutical compositions.

ALK Inhibitors for Treatment of ALK-Negative Cancer and Plasma Cell-Mediated Diseases

The European Patent Office published patent application EP4051288A1, filed by Universitetet I Oslo, covering ALK inhibitors for treating ALK-negative cancers and plasma cell-mediated diseases. The invention relates to therapeutic applications of ALK inhibitors beyond their typical indication. Publication date: March 25, 2026. This grant affects pharmaceutical companies developing cancer therapeutics in Europe.

One Pill Can Kill Initiative Launched at University of Arkansas at Monticello

Arkansas Attorney General Tim Griffin announced the launch of the One Pill Can Kill initiative at the University of Arkansas at Monticello, the 11th campus in Arkansas to join the program. The initiative provides student leaders with training on overdose prevention, recognition of overdose signs, and Narcan administration.

AG Coalition Urges Congress to Pass Combatting Illicit Xylazine Act

Arkansas Attorney General Tim Griffin co-led a bipartisan coalition of 41 state and territory attorneys general in sending a letter to congressional leadership urging passage of the Combatting Illicit Xylazine Act. The proposed legislation would classify xylazine (tranq), a veterinary tranquilizer increasingly mixed with fentanyl and heroin, as a Schedule III controlled substance. The letter emphasizes that Mexican cartels are trafficking xylazine into the U.S., contributing to rising fatal overdoses.